Ghazy Ramy Mohamed, Ashmawy Rasha, Hamdy Noha Alaa, Elhadi Yasir Ahmed Mohammed, Reyad Omar Ahmed, Elmalawany Dina, Almaghraby Abdallah, Shaaban Ramy, Taha Sarah Hamed N
Tropical Health Department, High Institute of Public Health, Alexandria University, Alexandria 21561, Egypt.
Department of Clinical Research, Maamoura Chest Hospital, Alexandria 21923, Egypt.
Vaccines (Basel). 2022 Feb 23;10(3):350. doi: 10.3390/vaccines10030350.
The coronavirus disease 2019 (COVID-19) pandemic has threatened global health and prompted the need for mass vaccination. We aimed to assess the efficacy and effectiveness of COVID-19 vaccines to prevent mortality and reduce the risk of developing severe disease after the 1st and 2nd doses. From conception to 28 June 2021, we searched PubMed, Cochrane, EBSCO, Scopus, ProQuest, Web of Science, WHO-ICTRP, and Google Scholar. We included both observational and randomized controlled trials. The pooled vaccine efficacy and effectiveness following vaccination, as well as their 95 percent confidence intervals (CI), were estimated using the random-effects model. In total, 22 of the 21,567 screened articles were eligible for quantitative analysis. Mortality 7 and 14 days after full vaccination decreased significantly among the vaccinated group compared to the unvaccinated group (OR = 0.10, ([95% CI, 0.04-0.27], I = 54%) and (OR = 0.46, [95% CI, 0.35-0.61], I = 0%), respectively. The probability of having severe disease one or two weeks after 2nd dose decreased significantly (OR = 0.29 [95% CI, 0.19-0.46], I = 25%) and (OR = 0.08 [95% CI, 0.03-0.25], I = 74%), respectively. The incidence of infection any time after the 1st and 2nd doses diminished significantly (OR = 0.14 [95% CI, 0.07-0.4], I = 100%) and (OR = 0.179 [95% CI, 0.15-0.19], I = 98%), respectively. Also, incidence of infection one week after 2nd dose decreased significantly, (OR = 0.04, [95% CI (0.01-0.2], I = 100%). After meta-regression, the type of vaccine and country were the main predictors of outcome [non-mRNA type, ß = 2.99, = 0.0001; country UK, ß = -0.75, = 0.038; country USA, ß = 0.8, = 0.02]. This study showed that most vaccines have comparable effectiveness, and it is purported that mass vaccination may help to end this pandemic.
2019冠状病毒病（COVID-19）大流行威胁着全球健康，促使人们需要进行大规模疫苗接种。我们旨在评估COVID-19疫苗在预防死亡以及降低首剂和第二剂接种后发生重症疾病风险方面的疗效和有效性。从研究构思到2021年6月28日，我们检索了PubMed、Cochrane、EBSCO、Scopus、ProQuest、Web of Science、WHO-ICTRP和谷歌学术。我们纳入了观察性研究和随机对照试验。使用随机效应模型估计接种疫苗后的合并疫苗效力和有效性及其95%置信区间（CI）。在筛查的21567篇文章中，共有22篇符合定量分析的条件。与未接种疫苗组相比，完全接种疫苗后7天和14天的死亡率在接种疫苗组中显著降低（OR = 0.10，[95%CI，0.04 - 0.27]，I = 54%）和（OR = 0.46，[95%CI，0.35 - 0.61]，I = 0%）。第二剂接种后1周或2周出现重症疾病的概率显著降低（OR = 0.29 [95%CI，0.19 - 0.46]，I = 25%）和（OR = 0.08 [95%CI，0.03 - 0.25]，I = 74%）。首剂和第二剂接种后任何时间的感染发生率均显著降低（OR = 0.14 [95%CI，0.07 - 0.4]，I = 100%）和（OR = 0.179 [95%CI，0.15 -
